TY - JOUR
T1 - Corticosteroid therapy for COVID-19
T2 - A systematic review and meta-analysis of randomized controlled trials
AU - Pulakurthi, Yashwitha Sai
AU - Pederson, John M.
AU - Saravu, Kavitha
AU - Gupta, Nitin
AU - Balasubramanian, Prasanth
AU - Kamrowski, Shelby
AU - Schmidt, Megan
AU - Vegivinti, Charan Thej Reddy
AU - Dibas, Mahmoud
AU - Reierson, Natalie L.
AU - Pisipati, Sailaja
AU - Joseph, Betsy Ann
AU - Selvan, Pragadeesh Thamarai
AU - Dmytriw, Adam A.
AU - Keesari, Praneeth Reddy
AU - Sriram, Varsha
AU - Chittajallu, Spandana
AU - Brinjikji, Waleed
AU - Katamreddy, Rewanth R.
AU - Chibbar, Richa
AU - Davis, Amber R.
AU - Malpe, Manashree
AU - Mishra, Hemant K.
AU - Kallmes, Kevin M.
AU - Hassan, Ameer E.
AU - Evanson, Kirk W.
N1 - Publisher Copyright:
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2021/5/21
Y1 - 2021/5/21
N2 - BACKGROUND: Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19. METHODS: We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection. RESULTS: A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections. CONCLUSION: Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients.
AB - BACKGROUND: Corticosteroid treatment is an effective and common therapeutic strategy for various inflammatory lung pathologies and may be an effective treatment for coronavirus disease 2019 (COVID-19). The purpose of this systematic review and meta-analysis of current literature was to investigate the clinical outcomes associated with corticosteroid treatment of COVID-19. METHODS: We systematically searched PubMed, medRxiv, Web of Science, and Scopus databases through March 10, 2021 to identify randomized controlled trials (RCTs) that evaluated the effects of corticosteroid therapies for COVID-19 treatment. Outcomes of interest were mortality, need for mechanical ventilation, serious adverse events (SAEs), and superinfection. RESULTS: A total of 7737 patients from 8 RCTs were included in the quantitative meta-analysis, of which 2795 (36.1%) patients received corticosteroids plus standard of care (SOC) while 4942 (63.9%) patients received placebo and/or SOC alone. The odds of mortality were significantly lower in patients that received corticosteroids as compared to SOC (odds ratio [OR] = 0.85 [95% CI: 0.76; 0.95], P = .003). Corticosteroid treatment reduced the odds of a need for mechanical ventilation as compared to SOC (OR = 0.76 [95% CI: 0.59; 0.97], P = .030). There was no significant difference between the corticosteroid and SOC groups with regards to SAEs and superinfections. CONCLUSION: Corticosteroid treatment can reduce the odds for mortality and the need for mechanical ventilation in severe COVID-19 patients.
UR - https://www.scopus.com/pages/publications/85106664264
UR - https://www.scopus.com/pages/publications/85106664264#tab=citedBy
U2 - 10.1097/MD.0000000000025719
DO - 10.1097/MD.0000000000025719
M3 - Article
C2 - 34011029
AN - SCOPUS:85106664264
SN - 0025-7974
VL - 100
SP - e25719
JO - Medicine
JF - Medicine
IS - 20
M1 - 20
ER -